Welcome to our dedicated page for Inhibikase Therapeutics news (Ticker: IKT), a resource for investors and traders seeking the latest updates and insights on Inhibikase Therapeutics stock.
Inhibikase Therapeutics, Inc. (IKT) is a clinical-stage pharmaceutical company dedicated to advancing medical treatments for Parkinson's disease and related disorders. Founded in 2008 and headquartered in Atlanta, Georgia, Inhibikase focuses primarily on the development of protein kinase inhibitors to modify the course of neurodegenerative diseases.
The company's flagship product candidate, IkT-148009, is a selective inhibitor of the non-receptor Abelson Tyrosine Kinases aimed at treating Parkinson's disease both inside and outside the brain. IkT-148009 is also being explored for its potential in treating dysphagia and neurogenic constipation, conditions often associated with Parkinson's disease.
Another noteworthy product in Inhibikase's pipeline is IkT-001Pro, a prodrug of the anti-cancer agent imatinib. Currently in preclinical development, IkT-001Pro aims to minimize gastrointestinal side effects commonly seen in cancer treatments. The company is also developing IkT-01427, which targets the causative virus of progressive multifocal leukoencephalopathy, and the IkT-148x series, meant for treating dementia with Lewy bodies and multiple system atrophy.
In recent news, Inhibikase announced that it would host a conference call on March 28, 2024, to discuss its latest developments. Furthermore, the company is reviewing IkT-001Pro's potential as a disease-modifying treatment for Pulmonary Arterial Hypertension. Financially, the company reported $2.8 million in research and development expenses and $2.0 million in selling, general, and administrative expenses for the quarter ended March 31, 2024.
For more information, you can contact the company through Milton H. Werner, PhD, President & CEO, at 678-392-3419 or via email at info@inhibikase.com. Investor relations are handled by Alex Lobo at Stern Investor Relations, Inc.
Inhibikase Therapeutics, a clinical-stage pharmaceutical company, provided updates on its Phase 2 '201' program for IkT-148009, aimed at treating Parkinson's disease, after the FDA lifted the clinical hold. The trial is progressing with 35 sites selected, expecting 11 to screen patients by April's end and 30 by Q2 2023. Importantly, state-of-the-art biomarker analyses for alpha-synuclein are now integrated into the trial. The safety and pharmacokinetics of a 200 mg dose have been evaluated in healthy volunteers, supporting its inclusion in the trial. Encouraging data from previous Phase 1b studies indicate potential positive treatment effects, although further confirmation is required. Future updates are planned as patient enrollment continues.
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) announced its participation in the 2023 Planet MicroCap Showcase on April 26, 2023, at the Horseshoe Hotel & Casino in Las Vegas. Dr. Milton Werner, President & CEO, and Joseph Frattaroli, CFO, will present at 1:00 PM PT. The company is focused on developing therapeutics targeting Parkinson's disease and related disorders, highlighting its lead program, IkT-148009, which inhibits Abelson Tyrosine Kinases (c-Abl). Inhibikase's pipeline also includes therapies for gastrointestinal disorders related to Parkinson's and innovative drug delivery technologies. The event offers an opportunity for investors to gain insights into the company’s strategies and advancements in neurodegeneration treatments.
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) reported financial results for 2022, highlighting a net loss of $18.1 million, or $0.72 per share, compared to a loss of $14.8 million in 2021. The company experienced a significant decrease in grant revenue, down to $0.1 million from $3.1 million. On a positive note, the FDA lifted clinical holds on its IkT-148009 programs for Parkinson's disease and Multiple System Atrophy (MSA). The company also successfully raised $10 million in early 2023 for ongoing clinical trials and product development. Cash position was reported at $23.1 million, expected to support operations into Q4 2024.
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) announced it will report its financial results for Q4 and full-year 2022 on March 31, 2023, after U.S. market close. A conference call and webcast will follow on April 3, 2023, at 8:00 a.m. ET to discuss the results and provide a corporate update. Inhibikase develops protein kinase inhibitor therapeutics aimed at modifying Parkinson's disease and related disorders. Their lead program, IkT-148009, targets treatment for Parkinson's within the brain, along with other cognitive and motor disorders linked to Abelson Tyrosine Kinases.
Inhibikase Therapeutics (Nasdaq: IKT) announced that CEO Milton Werner, Ph.D., will present at the International Conference on Alzheimer's and Parkinson's Diseases in Gothenburg, Sweden, from March 28 to April 1, 2023. The presentation, titled "Clinical Status of IKT-148009, A Potential Disease-Modifying Therapeutics for Parkinson's and Related Disorders," is scheduled for April 1, 2023, at 4:30 PM CET. Dr. Werner will discuss the role of c-Abl in neurodegeneration and the potential of IkT-148009 as a therapy to halt disease progression. He will also review efficacy and safety data from the Company’s Phase 1/1b study and ongoing Phase 2a trials.
On March 16, 2023, Inhibikase Therapeutics, Inc. (Nasdaq: IKT) announced a virtual R&D event scheduled for March 22, 2023, at 11:00 am ET. The event will feature the executive leadership discussing key clinical updates and milestones in their pipeline targeting Parkinson's disease and related disorders. Highlights include ongoing Phase 2a '201' trial for IkT-148009, a c-Abl tyrosine kinase inhibitor, and plans for future trials, including Multiple System Atrophy. A live webcast will be accessible on their website, with a replay available for 90 days.
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) announced progress in its '501' bioequivalence study for IkT-001Pro, a prodrug of imatinib mesylate, crucial for treating Chronic Myelogenous Leukemia (CML). As of March 15, 2023, the company completed dosing of three out of four planned cohorts. The study involves 59 healthy volunteers to evaluate safety and pharmacokinetics. IkT-001Pro displayed a favorable safety profile with only four mild adverse events. The company aims to complete the trial in Q2 2023 and engage the FDA about potential approval under the 505(b)(2) statute.
Inhibikase Therapeutics (Nasdaq: IKT) announced that the FDA has lifted the clinical hold on IkT-148009, enabling the commencement of a Phase 2 clinical trial in Multiple System Atrophy (MSA). Early studies indicate significant neuroprotective benefits from IkT-148009 through c-Abl inhibition. The planned Phase 2a '202' trial will assess the safety and efficacy of IkT-148009 in MSA patients over six months. MSA, affecting about 3 in 100,000 individuals, is characterized by rapid progression and no existing disease-modifying treatments. The Company is eager to initiate further studies to validate IkT-148009's therapeutic potential.
Inhibikase Therapeutics, a clinical-stage pharmaceutical company focused on Parkinson's disease, announced that CEO Milton Werner will present at the 11th Annual Alzheimer's & Parkinson's Drug Development Summit in San Francisco from February 21-23, 2023. The presentation will spotlight IkT-148009, a small molecule c-Abl kinase inhibitor, as a potential therapy for Parkinson's disease. Scheduled for February 23 at 10:45 AM PT, it will cover the drug's efficacy in animal models and the company’s ongoing Phase 2a trial strategy. Inhibikase aims to address neurodegeneration and related disorders through its innovative pipeline.
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) announced the closure of a registered direct offering and private placement, raising approximately $10 million. The company sold 6,744,187 shares at $0.86 per share and an additional 4,883,721 shares in a private placement. Unregistered warrants for 11,627,908 shares were also issued at an exercise price of $0.75. Proceeds will support corporate purposes, including clinical trials and product development. The offerings were priced at a premium to market, and the company plans to file a resale registration statement for the private placement securities.
FAQ
What is the current stock price of Inhibikase Therapeutics (IKT)?
What is the market cap of Inhibikase Therapeutics (IKT)?
What does Inhibikase Therapeutics, Inc. specialize in?
What is IkT-148009?
What is the purpose of IkT-001Pro?
Where is Inhibikase Therapeutics headquartered?
When was Inhibikase Therapeutics founded?
What other products are in Inhibikase's pipeline?
Who is the President & CEO of Inhibikase Therapeutics?
How can I contact Inhibikase Therapeutics for more information?
What are the latest financial figures for Inhibikase?
When is the next company conference call?
